Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J1OJ
|
||||
| Former ID |
DNCL003416
|
||||
| Drug Name |
Nintedanib
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
Boehringer Ingelheim
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C31H33N5O4
|
||||
| InChI |
InChI=1S/C31H33N5O4/c1-34-15-17-36(18-16-34)20-27(37)35(2)24-12-10-23(11-13-24)32-29(21-7-5-4-6-8-21)28-25-14-9-22(31(39)40-3)19-26(25)33-30(28)38/h4-14,19,32H,15-18,20H2,1-3H3,(H,33,38)/b29-28-
|
||||
| InChIKey |
XZXHXSATPCNXJR-ZIADKAODSA-N
|
||||
| CAS Number |
CAS 656247-17-5
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
14836969, 24116377, 44845702, 56435863, 76307381, 99431587, 99432362, 103654502, 109693020, 124343350, 124756932, 125163739, 126583666, 126724182, 131465103, 134964383, 135264167, 135267499, 136340157, 136920292, 139351111, 143498980, 144115708, 152236441, 152258852, 152344119, 160647702, 162011437, 162037383, 162202550, 162205188, 164041723, 172232574, 174531531, 174561006, 177748905, 178102559, 180386833, 188899496, 198986794, 223388548, 223471427, 223685460, 223704774, 223896861, 226755113, 226755114, 249738349, 249807126, 251963000
|
||||
| Target and Pathway | |||||
| Target(s) | Triple angiokinase | Target Info | Inhibitor | [533123] | |
| Vascular endothelial growth factor receptor 1 | Target Info | Modulator | [533123] | ||
| Basic fibroblast growth factor receptor 1 | Target Info | Modulator | [533123] | ||
| Anti-fibrotic kinase | Target Info | Inhibitor | [533123] | ||
| Platelet-derived growth factor receptor | Target Info | Modulator | [533123] | ||
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| HIF-1 signaling pathway | |||||
| Endocytosis | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| Transcriptional misregulation in cancer | |||||
| Rheumatoid arthritishsa04010:MAPK signaling pathway | |||||
| Adherens junction | |||||
| Signaling pathways regulating pluripotency of stem cells | |||||
| Regulation of actin cytoskeleton | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| Prostate cancer | |||||
| Melanoma | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Angiogenesis | ||||
| FGF signaling pathway | |||||
| Pathway Interaction Database | Glypican 1 network | ||||
| HIF-2-alpha transcription factor network | |||||
| S1P3 pathway | |||||
| VEGF and VEGFR signaling network | |||||
| VEGFR1 specific signals | |||||
| Signaling events mediated by VEGFR1 and VEGFR2glypican_1pathway:Glypican 1 network | |||||
| Syndecan-4-mediated signaling events | |||||
| N-cadherin signaling events | |||||
| FGF signaling pathway | |||||
| WikiPathways | Focal Adhesion | ||||
| Signaling by VEGF | |||||
| AngiogenesisWP51:Regulation of Actin Cytoskeleton | |||||
| Endochondral Ossification | |||||
| MAPK Signaling Pathway | |||||
| Mesodermal Commitment Pathway | |||||
| Hair Follicle Development: Induction (Part 1 of 3) | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Neural Crest Differentiation | |||||
| Signaling by FGFR | |||||
| References | |||||
| Ref 523930 | ClinicalTrials.gov (NCT01610869) Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer. U.S. National Institutes of Health. | ||||
| Ref 524516 | ClinicalTrials.gov (NCT01979952) Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF). U.S. National Institutes of Health. | ||||
| Ref 524899 | ClinicalTrials.gov (NCT02231164) LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational Research. U.S. National Institutes of Health. | ||||
| Ref 541221 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5936). | ||||
| Ref 556264 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.